Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of preparation method of olmesartan medoxomil with low solvent residue

A technology of olmesartan medoxomil and low solvent residue, applied in the field of medicine, can solve problems such as easy residue, achieve the effect of reducing harm to human body and solving the problem of solvent residue

Active Publication Date: 2016-05-25
烟台万润药业有限公司
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The solvent used for the purification and crystallization of olmesartan medoxomil is easy to remain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of olmesartan medoxomil with low solvent residue

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1) Take crude olmesartan medoxomil, use acetone to purify and crystallize (refer to CN102206208), and vacuum dry the olmesartan medoxomil after purification and crystallization for more than 3h under the conditions of ≤40°C and pressure ≥-0.08MPa, using a blast drying oven, The solvent residue of acetone was tested to be 0.4%.

[0031] 2) adding 1% absolute ethanol to the pre-dried olmesartan medoxomil, using a vibrating ultrafine pulverizer to pulverize, and pre-cooling the vibrating ultrafine pulverizer to -10°C to 0°C;

[0032] 3) Dry the pulverized olmesartan medoxomil for more than 2 hours in a vacuum drying oven under the conditions of ≤40°C and pressure >-0.08MPa.

[0033] Table 1 shows the comparison between the crushed particle size of olmesartan medoxomil and the acetone residue. Olmesartan medoxomil is pulverized to a particle size of D90=75μm or D90=60μm or D90=40μm or D90=20μm and then dried, and the acetone residues are all lower than the specified limit ...

Embodiment 2

[0037] 1) Take the crude olmesartan medoxomil, add acetonitrile with a mass ratio of 12 times the mass ratio of the crude olmesartan medoxomil, heat under reflux to dissolve, cool down to 0°C to 10°C after cooling and crystallization, and filter. The purified and crystallized olmesartan medoxomil was vacuum-dried for more than 4 hours using a rotary evaporator under the conditions of an inner temperature of ≤60° C. and a pressure of ≥-0.08 MPa, and the solvent residue of acetonitrile was detected to be 0.1%.

[0038] 2) Add 1.5% absolute ethanol to the pre-dried olmesartan medoxomil, pulverize with an airflow vortex micro-grinder, and cool the airflow vortex micro-grinder to -20-0°C in advance.

[0039] 3) Dry the pulverized olmesartan medoxomil at ≤60°C and normal pressure for more than 3 hours using a double cone.

[0040] The comparison relationship between the pulverized particle size of olmesartan medoxomil and the residual acetonitrile is shown in Table 2. Olmesartan me...

Embodiment 3

[0044] 1) Take the crude olmesartan medoxomil, add ethanol with a mass ratio of 13 times the crude olmesartan medoxomil, heat under reflux to dissolve, cool down to 0°C to 10°C after cooling and crystallization, and filter. The purified and crystallized olmesartan medoxomil was vacuum-dried for more than 4 hours in a vacuum drying oven at a temperature of ≤60° C. and a pressure of >-0.08 MPa, and the solvent residue of ethanol was detected to be 0.7%.

[0045] 2) Use a horizontal ball-milling ultra-fine pulverizer for pulverization, and pre-cool the horizontal ball-milling ultra-fine pulverizer to -10~0℃;

[0046] 3) Dry the pulverized olmesartan medoxomil at ≤60°C and normal pressure in a vacuum drying oven for more than 3 hours.

[0047] Table 3 shows the comparison between the crushed particle size of olmesartan medoxomil and the residual ethanol. Olmesartan medoxomil is pulverized to a particle size of D90=75μm or D90=60μm or D90=40μm or D90=20μm and then dried. The ethan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a preparation method of Olmesartan Medoxomi I with low solvent residue. The preparation method comprises following steps: an Olmesartan Medoxomi I crude product is prepared, and is subjected to purification crystallization, and predrying; Olmesartan Medoxomi I obtained via predrying is smashed; and the smashed Olmesartan Medoxomi I is dried. The preparation method is capable of removing solvent residue in Olmesartan Medoxomi I effectively.

Description

technical field [0001] The invention relates to a preparation method of olmesartan medoxomil with low solvent residue, and belongs to the field of medicine. Background technique [0002] Olmesartan medoxomil, molecular formula: C 29 H 30 N 6 O 6 , molecular weight: 558.6, structural formula: [0003] [0004] Olmesartan medoxomil is a new angiotensin II (AT II) receptor antagonist, developed by SankyoPharma in Japan and developed and produced by Forest Laboratories in the United States. It was first approved by the FDA in May 2002 for the treatment of hypertension. As Banicar, it was launched in Germany in October under the trade name OLMetec. As a new angiotensin II receptor antagonist (ARBs), olmesartan medoxomil has the effect of inhibiting angiotensin II. Olmesartan medoxomil is an oral tablet with few adverse reactions and high potency. It is currently used to treat hypertensive patients who cannot tolerate angiotensin-converting enzyme inhibitors (ACEI). [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D405/14
CPCC07D405/14
Inventor 孙宝佳李强王晔相龙明刘晓波徐艳平徐修祎
Owner 烟台万润药业有限公司